FDA CDER Compliance Office Answered Pandemic With Fewer Inspections, Greater Discretion
Fewer inspections but more warning letters, import alerts and drug-shortage discretions were seen as office sought to ameliorate COVID-19 impacts.
You may also be interested in...
US FDA will determine on a case-by-case basis whether its inability to inspect a facility because of the pandemic could result in 180-day exclusivity forfeiture for first generic filers.
FY2020 review highlights drop in inspections, preparations for growing backlog, and pandemic test of Janet Woodcock’s 21st Century proposition – developments that will likely reverberate in the years ahead.
The FDA must explain how it will prevent heparin adulteration as a virus kills pigs in China again.